Lamium Album

Dosage for Lamium Album is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels.

Diagnostic Testing

• Skin Prick Test (SPT): Usually, a single drop of a 1:10 or 1:20 w/v glycerinated extract is applied to the forearm or back. A sterile lancet is used to prick the skin through the drop. Results are read after 15–20 minutes.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a 0.02 mL to 0.05 mL dose of a much more dilute aqueous extract (e.g., 1:1000 w/v) may be injected into the dermis.

Immunotherapy (Hyposensitization)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are given subcutaneously once or twice weekly, with the dose increasing by 25% to 50% each time, provided the patient tolerates the previous dose without a significant local or systemic reaction.
• Maintenance Phase: Once the 'top dose' or maintenance dose is reached (often 0.5 mL of a 1:100 or 1:20 w/v extract), the interval between injections is increased to every 2 to 4 weeks. This phase usually lasts 3 to 5 years.

Lamium Album extracts are used in children, but the dosage must be approached with extreme caution.

• Children under 5: Immunotherapy is generally not recommended for very young children unless the allergic disease is severe, as they may have difficulty communicating the early symptoms of a systemic reaction.
• Children 5 and older: Dosing follows a similar build-up and maintenance schedule as adults but may start at even more conservative dilutions. The physician will adjust based on the child's weight and the severity of their allergic profile.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared primarily by the kidneys. However, the patient's overall health must be stable before administration.

Hepatic Impairment

No dosage adjustments are defined for hepatic impairment. The metabolic breakdown of allergenic proteins occurs via cellular proteolysis rather than hepatic cytochrome P450 pathways.

Elderly Patients

Elderly patients (over 65) require careful evaluation. The risk of systemic reactions may be higher if the patient has underlying cardiovascular disease. Doses may be increased more slowly during the build-up phase.

Lamium Album allergenic extracts are never for self-administration at home. They must be administered in a clinical setting equipped with emergency resuscitation equipment.

• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should never be frozen, as freezing can denature the proteins and alter potency.
• Administration: Subcutaneous injections should be given in the outer aspect of the upper arm. The site should be rotated between injections. The patient must remain in the clinic for at least 30 minutes post-injection for observation.
• Preparation: The vial should be gently swirled (not shaken) before drawing the dose to ensure a homogenous solution.

In the context of immunotherapy, a missed dose can disrupt the desensitization process:

• Short Delay (1-3 days): Usually, the scheduled dose can be given.
• Long Delay (over 1 week): The physician may need to repeat the previous dose or even reduce the dose to ensure safety, as the patient's tolerance may have slightly waned.
• Extended Absence: If several weeks are missed, the build-up phase may need to be partially restarted.

An overdose of Lamium Album extract (either due to a clinical error or an unexpected hyper-response) typically manifests as a severe systemic allergic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a sudden drop in blood pressure.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly is the primary treatment. Oxygen, intravenous fluids, and corticosteroids may also be required. Patients must be transported to an emergency department for extended monitoring.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your doctor if you feel unwell on the day of your scheduled injection.

Most patients undergoing testing or treatment with Lamium Album will experience some form of local reaction. These are generally considered part of the expected pharmacological response.

• Local Wheal and Flare: During skin testing, a small, itchy bump (wheal) surrounded by redness (flare) is the intended result. This usually resolves within 1–2 hours.
• Injection Site Redness: In immunotherapy, redness at the injection site is very common. It may feel warm to the touch and appear slightly swollen.
• Pruritus (Itching): Significant itching at the site of administration is expected. This can usually be managed with topical cold compresses or oral antihistamines.
• Mild Fatigue: Some patients report feeling slightly tired or 'run down' for a few hours following an immunotherapy injection.

• Large Local Reactions (LLR): Swelling at the injection site that exceeds 5–10 cm in diameter. These can be uncomfortable and may last for 24–48 hours.
• Nasal Congestion: A mild 'flare-up' of hay fever symptoms, including sneezing or a runny nose, shortly after the injection.
• Ocular Irritation: Itchy or watery eyes may occur as a systemic response to the allergen introduction.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Gastrointestinal Distress: Nausea, abdominal cramping, or mild diarrhea, which can be early signs of a systemic allergic response.
• Headache: Persistent or throbbing headache following treatment.

> Warning: Stop taking Lamium Album and call your doctor immediately if you experience any of these symptoms. These may indicate life-threatening anaphylaxis.

• Anaphylaxis: A rapid, systemic allergic reaction. It often begins with a 'sense of impending doom,' followed by respiratory and cardiovascular collapse.
• Angioedema: Deep tissue swelling, particularly of the lips, tongue, or throat, which can obstruct the airway.
• Bronchospasm: Severe wheezing, chest tightness, and difficulty breathing, similar to an acute asthma attack.
• Hypotension: A sudden drop in blood pressure, leading to dizziness, fainting (syncope), or shock.
• Tachycardia: An abnormally rapid heart rate as the body attempts to compensate for circulatory changes.

There is no evidence that long-term use of Lamium Album allergenic extracts causes organ damage, cancer, or chronic disease. The primary 'long-term' effect is the desired modulation of the immune system. However, patients should be monitored for:

• Persistent Sensitivity: In some cases, patients may not achieve full tolerance and may continue to experience reactions throughout the course of treatment.
• Subcutaneous Nodules: Occasionally, small, hard lumps may form under the skin at frequent injection sites. These are usually benign but should be reported to the physician.

FDA Black Box Warning for Allergenic Extracts:

Lamium Album allergenic extracts are associated with a risk of severe, life-threatening systemic reactions, including anaphylaxis. These reactions can occur even in patients who have previously tolerated the treatment well.

1. 1Supervision: Extracts must only be administered by healthcare professionals prepared to treat anaphylaxis.
2. 2Observation: Patients must be observed for at least 30 minutes after each injection.
3. 3Asthma Risk: Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.
4. 4Epinephrine: Patients should be prescribed an epinephrine auto-injector for use in case of a delayed systemic reaction after leaving the clinic.

Report any unusual symptoms to your healthcare provider. Even a 'mild' systemic reaction (like a few hives) must be reported, as it may precede a much more severe reaction at the next dose.

Lamium Album allergenic extracts are potent biological materials. They are not 'medicines' in the traditional sense but are tools to retrain the immune system. Safety depends entirely on accurate dosing and the patient's current physiological state. Patients must be 'clinically stable' before receiving an injection. This means no active asthma flares, no fever, and no significant acute illness.

No FDA black box warnings for Lamium Album specifically, but it falls under the general Black Box Warning for all Allergenic Extracts. This warning emphasizes that these products can cause severe anaphylaxis. It mandates that administration occurs in a facility with 'crash carts' and that patients with severe, steroid-dependent asthma should be excluded or treated with extreme caution.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. The risk is highest during the build-up phase and when switching to a new vial (which may have higher potency than an older, slightly degraded vial).
• Asthma Status: If a patient’s asthma is poorly controlled (FEV1 < 80% of predicted), the risk of a fatal reaction to an allergen injection increases exponentially. Injections should be withheld if the patient is experiencing increased wheezing or using their rescue inhaler more than usual.
• Cardiovascular Disease: Patients with pre-existing heart conditions are at higher risk because their bodies may not be able to compensate for the stress of a systemic reaction, and they may be taking medications (like beta-blockers) that complicate treatment.
• Infection: Do not administer Lamium Album if the patient has a fever or a significant respiratory infection, as this can lower the threshold for a systemic allergic reaction.

• Pre-Injection Screening: Before every dose, the nurse or doctor must ask about the reaction to the previous dose and check the patient's current lung function (often via peak flow meter).
• Post-Injection Observation: A mandatory 30-minute wait in the clinic is required. Most fatal reactions occur within this window.
• Skin Site Monitoring: The injection site should be checked for large local reactions before the patient leaves.

Generally, Lamium Album does not cause drowsiness or cognitive impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

Alcohol should be avoided on the day of an injection. Alcohol causes vasodilation (widening of blood vessels), which can potentially increase the rate of allergen absorption from the injection site and worsen the severity of an allergic reaction.

Treatment with Lamium Album can be stopped at any time without 'withdrawal' symptoms. However, stopping prematurely will result in the return of allergic symptoms upon exposure to the plant. If treatment is discontinued for more than a few weeks, it cannot be resumed at the same dose; a 'step-back' in dosing is required for safety.

> Important: Discuss all your medical conditions with your healthcare provider before starting Lamium Album. Ensure they know about any history of fainting, heart problems, or severe asthma.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These are generally contraindicated in patients receiving Lamium Album immunotherapy. Beta-blockers can increase the severity of anaphylaxis and, crucially, they make epinephrine (the primary treatment for anaphylaxis) much less effective. If a patient on a beta-blocker experiences a reaction, they may suffer from 'refractory' anaphylaxis that does not respond to standard emergency measures.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some evidence suggests that ACE inhibitors may increase the risk of systemic reactions or make them more difficult to treat, possibly by interfering with the body's natural compensatory mechanisms (like the renin-angiotensin system).
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to dangerously high blood pressure if an emergency occurs and epinephrine must be administered.

• Antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine): These do not cause a dangerous interaction, but they must be stopped 3 to 7 days before diagnostic skin testing. Antihistamines block the H1 receptors in the skin, which will suppress the 'wheal and flare' response, leading to a false-negative test result.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to antihistamines, these medications have potent H1-blocking properties and can interfere with the accuracy of allergy skin tests.
• Systemic Corticosteroids: Long-term use of oral steroids (like Prednisone) can suppress skin reactivity, though short-term or low-dose use may not significantly impact testing.

• Alcohol: As mentioned, alcohol should be avoided on injection days due to its vasodilatory effects.
• Spicy Foods: In some individuals, very spicy foods can trigger flushing or mild 'pseudo-allergic' symptoms that might be confused with a reaction to the extract.

• St. John's Wort: May theoretically interact with medications used to treat anaphylaxis, though clinical data is sparse.
• High-Dose Vitamin C: Some practitioners believe very high doses of Vitamin C have mild antihistamine properties, which could theoretically interfere with skin test sensitivity.

• Skin Prick Tests: Lamium Album administration itself is the test. No other common lab tests (like blood glucose or cholesterol) are typically affected by the extract.
• Total IgE: Immunotherapy may cause a transient rise in total IgE levels followed by a long-term decline, but this is an expected clinical marker rather than an 'interaction.'

Interaction Mechanism Summary

• Pharmacodynamic: Beta-blockers antagonize the beta-adrenergic receptors that epinephrine needs to stimulate to reverse anaphylaxis.
• Competitive Inhibition: Antihistamines compete for the same receptors that the histamine released during a skin test targets.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure or heart rhythm.

There are several conditions where the use of Lamium Album extract is strictly prohibited due to the risk of fatal outcomes:

1. 1Severe or Unstable Asthma: If a patient has a baseline FEV1 of less than 70% of predicted or has had a recent hospitalization for asthma, the risk of a fatal bronchospasm during an allergic reaction is too high.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The cardiovascular stress of a potential systemic reaction could trigger another cardiac event.
3. 3Hypersensitivity to Excipients: Patients with a known severe allergy to phenol (used as a preservative in many extracts) or glycerin should not receive these preparations.
4. 4Inability to Communicate: Patients who cannot describe symptoms of an early reaction (e.g., certain severe developmental delays or very young children) may be excluded for safety.

These conditions require a careful risk-benefit analysis by the specialist:

• Pregnancy: While immunotherapy is usually not started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia, it is often maintained if the patient is already at a stable dose.
• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with allergens could worsen certain autoimmune conditions, though this is rarely seen in practice.
• Malignancy: Patients with active cancer are generally not started on immunotherapy to avoid complicating their primary treatment.
• Beta-Blocker Therapy: If the patient cannot be switched to an alternative blood pressure medication, immunotherapy is often withheld.

Patients allergic to Lamium Album may show cross-reactivity with other members of the Lamiaceae family. This includes:

• Mint (Mentha)
• Sage (Salvia)
• Basil (Ocimum)
• Oregano (Origanum)
• Lavender (Lavandula)

If a patient has had a severe reaction to any of these herbs, the initial dose of Lamium Album extract should be even more conservative.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Lamium Album. Be honest about your asthma control and any heart medications.

FDA Pregnancy Category C (or equivalent under newer labeling rules). There are no adequate and well-controlled studies of Lamium Album extract in pregnant women.

• Risks: The primary risk is not the extract itself, but the potential for anaphylaxis. If the mother experiences a severe drop in blood pressure or respiratory distress, the fetus may suffer from hypoxia (lack of oxygen), which can lead to miscarriage or neurological damage.
• Clinical Practice: Allergists typically do not initiate Lamium Album testing or the build-up phase of immunotherapy during pregnancy. However, if a woman reaches the maintenance phase and then becomes pregnant, the treatment is often continued at the same (or slightly reduced) dose because the risk of a reaction is much lower at maintenance.

It is not known whether Lamium Album allergenic proteins are excreted in human milk. However, because these are large proteins that are degraded locally, it is highly unlikely that they would reach the infant in any significant or active form via breast milk. Breastfeeding is generally considered safe during immunotherapy, but the mother should be monitored for systemic reactions as usual.

• Approval: Lamium Album extracts are used in the pediatric population for both diagnosis and treatment.
• Age Considerations: Most specialists wait until a child is at least 5 years old to begin immunotherapy. This is primarily because younger children may not be able to articulate the 'itchy throat' or 'tight chest' that signals the start of a dangerous reaction.
• Growth: There is no evidence that allergenic extracts affect growth or development in children.

• Cardiovascular Reserve: Patients over 65 often have reduced cardiovascular reserve. A systemic reaction that a 20-year-old might survive easily could be fatal for a 70-year-old with underlying coronary artery disease.
• Polypharmacy: Older patients are more likely to be on beta-blockers or ACE inhibitors, which complicate the safety profile of Lamium Album.
• Renal/Hepatic: No specific changes in extract processing are expected, but the overall 'frailty' of the patient must be considered.

There are no specific guidelines for renal impairment. Since the extract is not a systemic drug cleared by the kidneys, the primary concern is simply the patient's ability to tolerate a potential systemic reaction and the emergency medications used to treat it.

No dosage adjustments are necessary. The proteins are broken down by ubiquitous proteases in the tissue and blood rather than the liver's microsomal enzyme system.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are planning to become pregnant or if your other doctors have started you on new heart medications.

Lamium Album extract acts as an exogenous antigen. In a sensitized individual, the primary molecular targets are Allergen-Specific IgE antibodies bound to the high-affinity FcεRI receptors on mast cells and basophils.

1. 1Recognition: The proteins (allergens) in the extract bind to the IgE.
2. 2Degranulation: This binding triggers a signal transduction cascade involving tyrosine kinases (like Syk), leading to the release of pre-formed mediators from granules (histamine, heparin) and the de novo synthesis of lipid mediators.
3. 3Immunotherapy Phase: Repeated exposure leads to the induction of T-regulatory (Treg) cells, which produce IL-10. This cytokine induces B-cells to switch from producing IgE to producing IgG4, which acts as a 'decoy' or 'blocking' antibody.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations of the extract produce larger wheals. In immunotherapy, higher doses are generally more effective at inducing tolerance but carry a higher risk of systemic reactions.
• Time to Onset:
• Diagnostic: 15–20 minutes for a wheal to appear.
• Therapeutic: It may take 6–12 months of immunotherapy before the patient notices a reduction in allergy symptoms.
• Duration of Effect: The diagnostic effect is transient (hours). The therapeutic effect of a completed 3–5 year course of immunotherapy can last for many years, or even a lifetime, after treatment stops.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | N/A (Interacts with IgE) |

| Half-life | Minutes to Hours (Proteolysis) |

| Tmax | 15-20 min (Skin reaction) |

| Metabolism | Tissue Proteases |

| Excretion | Lymphatic clearance of peptides |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides extracted from the Lamium album plant.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for the various allergenic fractions.
• Solubility: Soluble in aqueous buffers and glycerinated saline solutions.
• Preservatives: Typically contains 0.5% Phenol to prevent bacterial growth.

Lamium Album is classified as an Allergenic Extract. It belongs to the broader therapeutic category of Immunotherapy Agents. It is distinct from antihistamines or steroids because it modifies the underlying disease process rather than just masking the symptoms.